| 1 |
24718894 | Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. | 2014 Jun |
4 |
| 2 |
17161036 | Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. | 2007 Jan |
1 |
| 3 |
15882479 | Update on fused capromab pendetide imaging of prostate cancer. | 2005 Mar |
2 |
| 4 |
20641856 | 123I-Labeled (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl) ureido)pentyl)ureido)pentanedoic acid | 2004 |
1 |
| 5 |
20641935 | 123I-Labeled (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedoic acid | 2004 |
1 |
| 6 |
12114876 | The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer. | 2002 Jun |
2 |
| 7 |
11272670 | Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. | 2001 Mar |
4 |
| 8 |
18034550 | 111In-capromab pendetide: the evolution of prostate specific membrane antigen and the nuclear imaging of its 111In-labelled murine antibody in the evaluation of prostate cancer. | 2000 Jun |
1 |